![]() |
市場調查報告書
商品編碼
1861112
全球支架置入和擴張器材市場:市場規模、佔有率和趨勢分析(2025-2032 年)Stenting and Dilation Devices Market Size, Share & Trends Analysis | Global | 2025-2032 | Includes: Esophageal Stents, Duodenal Stents, Colonic Stents, and 3 more |
||||||
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
2025年全球支架置入及擴張裝置市場規模約6.89億美元。預計到2031年,該市場規模將超過8.47億美元,複合年成長率為3%。
該報告涵蓋食道支架和擴張球囊、十二指腸支架和擴張球囊以及結腸支架和擴張球囊。膽道和胰管支架及擴張球囊在內視鏡逆行性造影(ERCP)市場章節中單獨分析。
它量化了銷售量、平均售價(ASP)、市值、成長率和企業市場占有率,並深入分析了市場促進因素和限制因素、併購、技術趨勢等。報告提供了 2021 年至 2024 年的歷史數據以及到 2031 年的預測。
該研究範圍反映了技術創新、臨床適應症的擴大和材料的進步如何持續影響世界各地胃腸道 (GI) 手術中產品的採用和性能。
市場概覽
支架置入和擴張裝置在治療胃腸道狹窄和阻塞中發揮核心作用。這些裝置用於恢復食道、十二指腸和結腸惡性及良性疾病患者的管腔通暢性,並緩解其症狀。
近年來,隨著醫生們逐漸接受創傷較小的手術治療方法,市場也取得了顯著發展。置入術如今已成為過去主要依賴外科手術的病例的首選治療方案。內視鏡治療方案日益偏好,這與醫學界更廣泛的理念轉變不謀而合,即縮短住院時間、降低併發症風險並加快康復速度。
從裸金屬支架到全覆膜自膨式金屬支架(SEMS)的轉變,標誌著支架安全性和可回收性顯著提高的明顯趨勢。生物可吸收支架和藥物釋放型支架的研發正在拓展治療方法選擇,早期臨床證據表明,這些支架能夠提高患者耐受性並降低血管再阻塞率。
同時,擴張球囊作為狹窄治療的輔助性治療或單一療法,其應用日益廣泛。多級球囊系統可使用單一器械進行分階段擴張,進而提高手術效率和療效,進而提昇平均售價,並促進市場價值的成長。
總體而言,全球支架植入和擴張裝置市場反映了臨床療效、材料創新和成本效益的整合,使這些技術成為微創治療的關鍵推動因素。
市場促進因素
拓展用途和適應症
醫師對支架和擴張球囊的應用範圍已從傳統的腫瘤治療擴展到良性食道狹窄、肥胖併發症和術後滲漏等新的治療領域。臨床研究表明,十二指腸置入術通常比外科手術治療阻塞性狹窄創傷更小、成本更低,因此支持其在安寧療護和根治性治療中更廣泛地應用。
隨著醫療保健系統優先考慮以價值為導向的治療結果,置入術已成為對成本敏感的患者和支付方的首選治療方案。同樣,人們對逆流相關疾病的認知不斷提高,以及無需開放性手術即可加強薄弱組織的益處,也促使食道擴張球囊的應用日益廣泛。
這些全球趨勢正在推動全球手術量增加,尤其是在醫療系統正在加強內視鏡檢查能力的地區。
新技術
技術創新是全球支架置入和擴張器材市場的主要成長要素。全覆膜金屬支架的引入提高了取出效率,減少了組織浸潤,並降低了併發症率。到2025年,生物可吸收支架和藥物釋放型支架將從初步試驗走向商業化應用,早期使用者報告稱,這些支架能夠改善患者的治療效果。
材料科學的進步不斷推動更輕、更強的合金和聚合物塗層的研發,從而增強支架的柔韌性和徑向支撐力,同時最大限度地減少支架移位。這些市場發展趨勢提高了手術成功率和長期通暢率,進而促進了市場的持續成長。
多級擴張球囊
外科醫生越來越傾向於使用多階段擴張球囊而不是單階段設計,因為多階段擴張球囊可以控制地逐步擴張狹窄處,臨床研究表明,這可以減少組織損傷和穿孔風險,並提高管腔擴張的穩定性。
多級球囊系統比傳統球囊系統更具價值,由於其卓越的安全性和有效性,正在主要市場廣泛應用。隨著此類球囊系統成為標準醫療設備,預計將提升整體市場價值,並推動高級產品區隔市場的成長。
市場限制
儘管成長前景可觀,但仍有幾個因素限制著市場擴張。
成本壓力和報銷課題
不同地區的保險報銷結構差異顯著,在一些新興市場,胃腸道置入術的保險覆蓋範圍仍然有限。面臨預算限制的醫院通常優先考慮可重複使用和成本較低的方案,這降低了主動式支架(ASP)的成長潛力。
臨床培訓和設備使用
在資源匱乏的地區,高品質的內視鏡實驗室和訓練有素的工作人員的取得並不穩定,複雜的支架置入手術的學習曲線可能會限制新技術的採用,尤其是生物可吸收支架。
裝置遷移和併發症
儘管材料的改進減少了併發症,但支架移位和阻塞仍然是臨床上需要關注的問題。這些問題會導致再次手術,增加治療總成本,並影響患者對更成熟設計的偏好。
總體而言,市場成長高度依賴培訓、證據產生和擴大報銷範圍,尤其是在新興地區。
市場覆蓋範圍和數據範圍
定量範圍
市場規模、市佔率、市場預測
成長率、銷售量、平均售價(ASP)
定性範圍
成長趨勢、市場限制和技術進步
競爭分析、併購
公司簡介及產品系列
手術數量和技術趨勢
調查期
數據來源
對腸胃病學家和行業專家的初步訪談、監管和醫院採購資料、進出口資料、iData Research 內部資料庫
調查方法
市場收入模型是根據單位數量乘以平均售價 (ASP) 計算得出的,並使用每種支架和球囊類別的手術數據、使用率和交易假設檢驗。
目標市場及區隔
食道支架
十二指腸支架
結腸支架
食道擴張球囊
十二指腸擴張球囊
結腸擴張球囊
競爭分析
全球支架植入和擴張裝置市場集中度適中,少數幾家跨國公司佔了全球收入的大部分。
到2025年,波士頓科學公司將引領市場,佔約50%的市場。波士頓科學公司豐富的內視鏡配件產品組合使醫院能夠從單一供應商採購多個類別的設備,從而增強品牌忠誠度並簡化採購流程。波士頓科學公司的支架技術因其臨床可靠性和全球分銷網路而廣受認可。
庫克醫療(Cook Medical)在2025年排名第二,在擴張球囊和特殊食道應用領域保持強大的市場地位。該公司提供三款食道球囊產品線,其中包括專為治療賁門失弛症而設計的Quantum TTC®擴張球囊。庫克醫療專注於此臨床領域,使其能夠供應全球大部分用於治療食道動力障礙的球囊。
奧林巴斯公司已收購韓國胃腸道金屬支架製造商泰雄醫療株式會社。此次收購將豐富奧林巴斯的產品線並拓展其分銷網路,尤其是在歐洲地區。奧林巴斯的Niti-S™和COMVI™產品線包括用於食道、十二指腸和結腸的全覆膜和半覆膜支架。憑藉極具競爭力的價格和遍佈25個國家的本地經銷商網路,奧林巴斯的產品對注重成本的醫療機構極具吸引力。
其他活動包括在特定地域或產品類型上運作的區域性製造商。市場的集中性促使企業持續投資於品質、證據累積和產品差異化,同時也提高了新競爭者的進入門檻。
科技與臨床趨勢
由於全覆膜支架和藥物釋放型支架具有更好的可移除性和更少的組織浸潤,它們正逐漸取代老式的裸金屬支架。
生物可吸收支架技術尚處於早期應用階段,在短期適應症方面展現出良好的應用前景。
由於其優異的安全性,多級擴張球囊正逐漸成為良性狹窄的標準治療方法。
輸送系統的改進可以實現更精確的定位,縮短手術時間,並減少透視輻射暴露。
材料創新,包括聚合物-金屬混合框架,提高了徑向力,同時最大限度地減少了患者的不適感。
臨床重點正轉向基於證據選擇支架類型和覆蓋範圍,並以規範實踐模式的國際指南為支持。
地區
本期內容涵蓋全球範圍,包括北美、歐洲、亞太地區、拉丁美洲以及中東和非洲的詳區隔析。
調查方法附錄與簡稱
圖表清單
圖表列表
調查方法
全球關稅的影響
支架置入及擴張裝置市場
The global stenting and dilation device market was valued at approximately $689 million in 2025. The market is projected to grow at a compound annual growth rate (CAGR) of 3%, reaching more than $847 million by 2031.
This report covers esophageal stents and dilation balloons, duodenal stents and dilation balloons, and colonic stents and dilation balloons. Biliary and pancreatic stents and dilation balloons are analyzed separately under the endoscopic retrograde cholangiopancreatography (ERCP) market chapter.
The report quantifies units, average selling prices (ASPs), market values, growth rates, and company shares, and it provides a detailed analysis of market drivers and limiters, mergers and acquisitions, and technology trends. It includes historical data from 2021 to 2024 and forecasts to 2031.
The scope reflects how technological innovation, expanding clinical indications, and material advancements continue to shape product adoption and performance across gastrointestinal (GI) procedures worldwide.
Market Overview
Stenting and dilation devices are central to the management of strictures and obstructions within the gastrointestinal tract. These devices are used to restore luminal patency and relieve symptoms in patients with malignant and benign conditions of the esophagus, duodenum, and colon.
In recent years, the market has evolved significantly as physicians adopt less invasive alternatives to surgery. Stenting procedures now represent a primary treatment option in cases where surgical intervention once dominated. The growing preference for endoscopic solutions aligns with the medical community's broader shift toward shorter hospital stays, lower complication risks, and reduced recovery times.
The transition from bare-metal to fully covered self-expanding metal stents (SEMS) underscores a clear trend toward improved safety and retrievability. Developments in bioabsorbable and drug-eluting stents are expanding the therapeutic landscape, with early clinical evidence showing better patient tolerance and reduced restenosis rates.
Meanwhile, dilation balloons continue to gain traction as an adjunct or standalone therapy for stricture management. Multi-stage balloon systems that enable progressive dilation through a single device are improving procedural efficiency and outcomes, supporting stronger ASPs and contributing to market value growth.
Overall, the global stenting and dilation market reflects the convergence of clinical efficacy, material innovation, and cost-effectiveness, positioning these technologies as key enablers of minimally invasive care.
Market Drivers
Expansion of Uses and Indications
Physician adoption of stents and dilation balloons has expanded beyond traditional oncologic applications into new therapeutic areas, including benign esophageal strictures, bariatric complications, and post-surgical leaks. Clinical studies have demonstrated that duodenal stenting is often less invasive and more cost-effective than surgical alternatives for managing obstructive strictures, supporting its broader use in both palliative and curative settings.
As healthcare systems prioritize value-based outcomes, stenting has become a preferred treatment pathway for cost-sensitive patients and payers. Likewise, the adoption of esophageal dilation balloons continues to rise as awareness grows around reflux-related disorders and the benefits of reinforcing weakened tissue without open surgery.
These trends are expanding procedural volumes globally, particularly in regions where healthcare systems are strengthening endoscopic capabilities.
New Technologies
Innovation is a primary growth driver for the global stenting and dilation market. The introduction of fully covered metal stents has improved removal capability, reduced tissue ingrowth, and lowered complication rates. By 2025, bioabsorbable and drug-eluting stents had moved from pilot studies into commercial availability, with early adopters reporting improved patient outcomes.
Material science continues to advance, with lighter and stronger alloys and polymer coatings enhancing device flexibility and radial force while minimizing migration. These developments are improving procedural success and contributing to better long-term patency rates, fueling sustained market growth.
Multi-Stage Dilation Balloons
Surgeons increasingly prefer multi-stage dilation balloons over single-stage designs because they allow gradual, controlled dilation of strictures. This method has been clinically shown to reduce tissue trauma and perforation risk while improving lumen expansion consistency.
Although multi-stage systems carry higher ASPs than conventional balloons, their superior safety and effectiveness are driving adoption across major markets. As these devices become standard practice, they are expected to elevate overall market value and support the growth of the premium product segment.
Market Limiters
Despite promising growth, several factors continue to constrain broader market expansion.
Cost Pressures and Reimbursement Challenges
Reimbursement structures vary widely across regions, and in some developing markets, coverage for GI stenting procedures remains limited. Hospitals facing budget constraints often prioritize reusable or lower-cost options, reducing ASP growth potential.
Clinical Training and Access to Equipment
In lower-resource regions, access to high-quality endoscopy suites and trained personnel remains inconsistent. The learning curve for complex stenting procedures can limit adoption, particularly for emerging technologies like bioabsorbable stents.
Device Migration and Complications
While material improvements have reduced complications, stent migration and occlusion remain clinical concerns. These issues can lead to repeat procedures, increasing total cost of care and influencing product preference toward more established designs.
Overall, market growth depends heavily on training, evidence generation, and reimbursement expansion, particularly in emerging regions.
Market Coverage and Data Scope
Quantitative Coverage
Market size, market shares, and market forecasts
Growth rates, units sold, and average selling prices (ASPs)
Qualitative Coverage
Growth trends, market limiters, and technology advancements
Competitive analysis, mergers and acquisitions
Company profiles and product portfolios
Procedure numbers and technology trends shaping adoption
Time Frame
Data Sources
Primary interviews with gastroenterologists and industry experts, regulatory and hospital procurement data, import and export data, and the iData Research internal database.
Method Note
Market revenues are modeled from units multiplied by ASP, validated with procedural data, utilization rates, and replacement assumptions for each stent and balloon category.
Markets Covered and Segmentation
Esophageal Stent
Duodenal Stent
Colonic Stent
Esophageal Dilation Balloon
Duodenal Dilation Balloon
Colonic Dilation Balloon
Competitive Analysis
The global stenting and dilation device market is moderately concentrated, with a few multinational firms accounting for the majority of global revenue.
Boston Scientific led the market in 2025, holding approximately 50% of total market share. The company's broad endoscopic accessories portfolio enables hospitals to source multiple device categories from a single vendor, reinforcing brand loyalty and simplifying procurement. Boston Scientific's stent technologies are widely recognized for their clinical reliability and global distribution reach.
Cook Medical ranked second in 2025, maintaining a strong presence in dilation balloons and specialized esophageal applications. The company offers three esophageal balloon lines, including Quantum TTC(R) dilation balloons, designed specifically for treating achalasia. Through its focus on this clinical niche, Cook Medical supplies a large proportion of balloons used for esophageal motility disorders worldwide.
Olympus Corporation held the third-largest position, strengthened by its acquisition of Taewoong Medical Co., Ltd., a South Korean manufacturer of GI metallic stents. This acquisition expanded Olympus's product range and geographic reach, especially across Europe. The company's Niti-S(TM) and COMVI(TM) product lines include fully and partially covered stents for esophageal, duodenal, and colonic use. Olympus's competitive pricing and partnerships with national distributors across 25 countries make its portfolio appealing to cost-conscious healthcare systems.
Other participants include regional manufacturers active in limited geographies or product types. The concentrated nature of the market encourages continued investment in quality, evidence generation, and product differentiation, while raising the entry barrier for new competitors.
Technology and Practice Trends
Fully covered and drug-eluting stents are replacing older bare-metal designs due to improved removability and reduced tissue ingrowth.
Bioabsorbable stent technologies are in early adoption stages, showing promise for temporary indications.
Multi-stage dilation balloons are becoming standard for benign strictures due to superior safety outcomes.
Improved delivery systems now allow more precise placement, reducing procedural time and fluoroscopy exposure.
Material innovation, including hybrid polymer-metal frameworks, is enhancing radial force while minimizing patient discomfort.
Clinical focus is shifting toward evidence-based selection of stent type and coverage, supported by international guidelines that standardize practice patterns.
Geography
This edition provides global coverage, including detailed breakdowns for North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
Methodology Appendix and Acronym Glossary
Where are the largest and fastest-growing opportunities within the global stenting and dilation device market, and which categories are expected to gain share through 2031?
How are technological innovations, including bioabsorbable materials and drug-eluting designs, reshaping product performance and clinical decision-making?
What are the economic and procedural trends influencing adoption across regions, and how do reimbursement models affect market potential?
How are training access, material advancements, and patient safety outcomes influencing hospital purchasing decisions?
Which product types and manufacturers are most strongly positioned to benefit from the ongoing shift toward minimally invasive GI therapies?
How can suppliers leverage multi-stage balloon innovations and next-generation stent designs to strengthen their market position and pricing strategy?
The Global Stenting & Dilation Device Market Report from iData Research answers these questions with procedure-aware modeling, company share analysis, and price benchmarking. Use it to quantify demand, plan portfolio strategy, guide pricing decisions, and identify the next phase of global growth opportunities.
Table Of Contents
List Of Figures
List Of Charts
Research Methodology
Impact Of Global Tariffs
Stenting & Dilation Market